DAY ONE SOCIETA A RESPONSABILITA LIMITATA

Their core work

DAY ONE is a Rome-based innovation consultancy specializing in technology transfer and commercialization support for EU-funded research. Rather than conducting research themselves, they help scientific teams translate lab results into viable business propositions — developing business plans, market assessments, and commercialization strategies. Their involvement across radically different technical domains (quantum computing, diabetes management, cervical cancer diagnostics, smart buildings) confirms they provide cross-cutting business and innovation services rather than domain-specific technical expertise. Their frequent presence in ERC Proof of Concept and Coordination & Support Actions reflects this advisory role.

What they specialise in

How they've shifted over time

DAY ONE's early projects (2016–2020) focused on industrial manufacturing and materials science commercialization, including STREAM-0D (zero-defect manufacturing) and BioWings (electrostrictive smart materials). From 2021 onward, their portfolio shifted dramatically toward health-tech and deep-tech commercialization — diabetes management devices, cervical cancer diagnostics, quantum computing, and smart buildings. This evolution suggests the company has moved from supporting incremental industrial innovation toward higher-risk, higher-reward frontier technologies where the gap between lab and market is larger and commercialization expertise is more valuable.

DAY ONE is positioning itself as a go-to commercialization partner for frontier research spinoffs, particularly in medical devices and quantum technologies, where scientific breakthroughs need structured pathways to market.

How they like to work

DAY ONE operates almost exclusively as a participant (10 of 11 projects), taking support roles in consortia rather than leading them. They coordinated only one project (PRISMA), a small ERC-POC on diabetes management. With 40 unique partners across 18 countries, they maintain a broad but non-repetitive network — typical of a service provider that joins different teams project by project rather than building a fixed cluster of repeat collaborators. This makes them easy to onboard: they are accustomed to integrating into diverse consortia quickly.

DAY ONE has collaborated with 40 distinct partners across 18 countries, giving them a wide European network. Their connections span universities, research institutes, and SMEs across diverse technical fields, though no single geographic cluster dominates beyond their Italian base.

What sets them apart

DAY ONE's defining strength is domain-agnostic commercialization expertise — they can support technology transfer whether the underlying science is quantum physics, medical imaging, or solar energy. This versatility is rare among SMEs, which typically specialize in one sector. For consortium builders, DAY ONE offers a proven track record of handling the business case, exploitation planning, and market validation work packages that many research-heavy teams struggle with, and they bring this capability with the administrative flexibility of a small company.

Highlights from their portfolio

• PRISMA
  Their only coordinated project — an ERC Proof of Concept developing a micro-mechanical pump for next-generation diabetes management with three-hormone therapy.
• SMART2B
  Their largest funded project (EUR 212,625) and longest recent engagement (2021-2024), focused on retrofitting smartness into existing commercial and residential buildings.
• GENESIS
  Represents their push into quantum technology commercialization — superconducting transistors with applications in quantum computing and supercomputing.